- Previous Close
1.9500 - Open
1.9400 - Bid 1.4100 x 100
- Ask 2.3800 x 200
- Day's Range
1.8201 - 1.9700 - 52 Week Range
0.5300 - 4.4900 - Volume
182,693 - Avg. Volume
269,531 - Market Cap (intraday)
25.277M - Beta (5Y Monthly) 4.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
www.nexalin.comRecent News: NXL
View MorePerformance Overview: NXL
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NXL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NXL
View MoreValuation Measures
Market Cap
25.28M
Enterprise Value
22.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
103.78
Price/Book (mrq)
6.88
Enterprise Value/Revenue
132.36
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-123.41%
Return on Equity (ttm)
-221.05%
Revenue (ttm)
168.72k
Net Income Avi to Common (ttm)
-7.61M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.32M